Published in Blood on October 09, 2008
Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood (2008) 1.64
Imputation of exome sequence variants into population- based samples and blood-cell-trait-associated loci in African Americans: NHLBI GO Exome Sequencing Project. Am J Hum Genet (2012) 1.60
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood (2014) 1.55
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med (2013) 1.36
Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci U S A (2014) 1.08
The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood (2014) 0.93
Hematological and acute-phase responses to diet-induced obesity in IL-6 KO mice. Cytokine (2011) 0.88
Role of tumor suppressor p53 in megakaryopoiesis and platelet function. Exp Hematol (2011) 0.87
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. Elife (2015) 0.84
Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood (2014) 0.82
JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood (2014) 0.81
Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia. Mol Ther (2009) 0.80
Extracellular domain N-glycosylation controls human thrombopoietin receptor cell surface levels. Front Endocrinol (Lausanne) (2011) 0.79
Platelet studies in autism spectrum disorder patients and first-degree relatives. Mol Autism (2015) 0.78
Mpl traffics to the cell surface through conventional and unconventional routes. Traffic (2014) 0.78
Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Res (2016) 0.77
Mpl and thrombocytosis: levels matter. Blood (2009) 0.77
Toward a universal treatment for cancer: cell inflation assisted chemotherapy. Cancer Med (2013) 0.77
The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin. Front Endocrinol (Lausanne) (2017) 0.75
Mouse models of diseases of megakaryocyte and platelet homeostasis. Mamm Genome (2011) 0.75
Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. Front Endocrinol (Lausanne) (2017) 0.75
Identification of MPL R102P Mutation in Hereditary Thrombocytosis. Front Endocrinol (Lausanne) (2017) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med (2008) 12.68
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature (2011) 5.45
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5.30
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci (2009) 3.74
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood (2007) 3.52
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13
A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol (2010) 3.09
Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood (2006) 2.88
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med (2007) 2.85
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 2.79
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet (2003) 2.76
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood (2006) 2.74
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood (2014) 2.72
The mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh signal transduction during development. Curr Biol (2009) 2.63
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood (2010) 2.61
A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature (2002) 2.50
Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell (2002) 2.48
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood (2007) 2.44
Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. Lancet Neurol (2006) 2.38
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A (2009) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood (2010) 2.33
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27
Paracrine Hedgehog signaling in cancer. Cancer Res (2009) 2.21
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol (2011) 2.20
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19
The hedgehog signaling pathway in cancer. Clin Cancer Res (2006) 2.15
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica (2008) 2.05
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood (2004) 2.01
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res (2008) 1.95
Coordinated loading of IRG resistance GTPases on to the Toxoplasma gondii parasitophorous vacuole. Cell Microbiol (2010) 1.94
Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol (2010) 1.93
Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol (2008) 1.92
Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma (2008) 1.90
IL-27 limits IL-2 production during Th1 differentiation. J Immunol (2006) 1.89
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood (2006) 1.89
Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer (2007) 1.85
Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. Mol Cell Biol (2010) 1.81
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal (2011) 1.81
Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity (2007) 1.79
Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res (2011) 1.72
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res (2005) 1.69
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood (2013) 1.69
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma (2011) 1.68
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica (2008) 1.63
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell (2009) 1.61
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood (2012) 1.58
Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. Am J Pathol (2006) 1.57
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Hedgehog signaling regulates the generation of ameloblast progenitors in the continuously growing mouse incisor. Development (2010) 1.55
Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS. Proc Natl Acad Sci U S A (2014) 1.54
Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol (2005) 1.54
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
The p47 GTPases Igtp and Irgb10 map to the Chlamydia trachomatis susceptibility locus Ctrq-3 and mediate cellular resistance in mice. Proc Natl Acad Sci U S A (2006) 1.49
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood (2004) 1.48
Acute myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator of mammary gland function. Mol Cell Biol (2006) 1.48
Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol (2005) 1.48
Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. Stroke (2004) 1.47
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica (2008) 1.45
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J Exp Med (2010) 1.41
B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol (2013) 1.39
Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalus. Mol Cell Biol (2005) 1.39
Suppressor of fused regulates Gli activity through a dual binding mechanism. Mol Cell Biol (2004) 1.38
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood (2003) 1.35
IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med (2007) 1.34
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Balance of Irgm protein activities determines IFN-gamma-induced host defense. J Leukoc Biol (2009) 1.33
IRG and GBP host resistance factors target aberrant, "non-self" vacuoles characterized by the missing of "self" IRGM proteins. PLoS Pathog (2013) 1.33
Long-term effects of specialized stroke care with telemedicine support in community hospitals on behalf of the Telemedical Project for Integrative Stroke Care (TEMPiS). Stroke (2008) 1.33
Kinome siRNA screen identifies regulators of ciliogenesis and hedgehog signal transduction. Sci Signal (2008) 1.33